Focused on building reliable datasets, financial models, and research tools for value-minded investors. Committed to turning complex data into practical guidance for value-investing and long-term wealth.
Dr. Charlie Tian is the founder and CEO of GuruFocus.com, a leading global investment research platform established in 2004. With a Ph.D. in physics, Dr. Tian transitioned from science to finance, applying a data-driven, disciplined approach to value investing.
BiomaximaFRA:944 +4.53%51 Days Inventory is 208.42 as of Mar. 2026, which is 29% above its 10-year median of 161.28. GuruFocus rates FRA:944 with a GF Score™ of 51/100 and a GF Value™ of €2.99. The stock has 4 warning signs investors should review. Among 179 Medical Diagnostics & Research companies, Biomaxima ranks worse than 81.56% on this metric.
Days Inventory is also known as Days Sales of Inventory (DSI). Biomaxima's Average Total Inventories for the
three
months ended in Mar. 2026 was €3.25 Mil. Biomaxima's Cost of Goods Sold for the
three
months ended in Mar. 2026 was €1.42 Mil.
Hence, Biomaxima's Days Inventory for the
three
months ended in Mar. 2026 was 208.42.
The historical rank and industry rank for Biomaxima's Days Inventory or its related term are showing as below:
FRA:944'
s Days Inventory Range Over the Past 10 Years
Min: 54.66 Med: 161.28 Max: 196.25
Current: 161.64
During the past 13 years, Biomaxima's highest Days Inventory was 196.25. The lowest was 54.66. And the median was 161.28.
FRA:944's Days Inventory is ranked worse than 81.56% of 179
companies
in the Medical Diagnostics & Research industry
Industry Median: 65.04
vs FRA:944: 161.64
Biomaxima's Days Inventory
increased
from Mar. 2025 (166.17) to Mar. 2026 (208.42).
It might indicate that Biomaxima's sales slowed down.
Inventory Turnover measures how fast the company turns over its inventory within a year.
Biomaxima's Inventory Turnover for the
three
months ended in Mar. 2026 was 0.44.
Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biomaxima's Inventory-to-Revenue for the
three
months ended in Mar. 2026 was 1.01.
Biomaxima (FRA:944) Days Inventory Explanation
Days Inventory indicates the liquidity of the inventory. Generally, a lower Days Inventory is preferred as it indicates a shorter duration to clear off the inventory. An increase of the ratio may indicate the company's sales slowed. Similar ratios related to Days Inventory are:
1. Inventory Turnover measures how fast the company turns over its inventory within a year.
Biomaxima's Inventory Turnover for the
three
months ended in Mar. 2026 is calculated as
2. Inventory-to-Revenue determines the ability of a company to manage their inventory levels. It measures the percentage of Inventories the company currently has on hand to support the current amount of Revenue.
Biomaxima's Inventory to Revenue for the
three
months ended in Mar. 2026 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Be Aware
A lot of business are seasonable. It makes more sense to compare Days Inventory from the same period in the previous year instead of from the previous quarter.
Biomaxima Days Inventory Related Terms
Biomaxima Days Inventory Historical Data
* Premium members only.
The historical data trend for Biomaxima's Days Inventory can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
FRA:944 vs TMO, DHR, IDXX: Days Inventory Comparison
For the Diagnostics & Research subindustry, Biomaxima's Days Inventory, along with its competitors' market caps and Days Inventory data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Biomaxima Days Inventory vs Medical Diagnostics & Research Industry
For the Medical Diagnostics & Research industry and Healthcare sector, Biomaxima's Days Inventory distribution charts can be found below:
* The bar in red indicates where Biomaxima's Days Inventory falls into.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Biomaxima (FRA:944) has a Days Inventory of 208.42 as of Mar. 2026. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Biomaxima and its competitors. This is 29% above median its historical median of 161.28. Over the past decade, Biomaxima's Days Inventory has ranged from 54.66 to 196.25. According to the industry distribution chart, Biomaxima ranks #146 out of 179 companies in the Medical Diagnostics & Research industry, placing it in the top 81.6%.
Is Biomaxima's Days Inventory too high?
Biomaxima's current Days Inventory of 208.42 is 29% above median its 10-year median of 161.28. Over the past 10 years, this metric has ranged from a low of 54.66 to a high of 196.25. The Medical Diagnostics & Research industry median Days Inventory is 65.04. Biomaxima's value of 208.42 is 220.4% above this industry median. Based on the distribution chart, Biomaxima ranks #146 out of 179 companies in the Medical Diagnostics & Research industry, which is in the bottom quartile relative to peers. Overall, Biomaxima has a GF Score™ of 51/100, reflecting its overall financial health beyond just this single metric.
How does Biomaxima's Days Inventory compare to TMO and DHR?
According to the Medical Diagnostics & Research industry distribution chart, Biomaxima ranks #146 out of 179 companies for Days Inventory. This places Biomaxima in the lower half of its industry. The industry median Days Inventory is 65.04. Biomaxima's value of 208.42 is 220.4% above this benchmark. Historically, Biomaxima's own Days Inventory has ranged from 54.66 to 196.25 over the past decade. While the company's 10-year median is 161.28 vs. the industry median of 65.04, Biomaxima has consistently been above the industry average. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Days Inventory for a Medical Diagnostics & Research company?
The median Days Inventory among Medical Diagnostics & Research companies is 65.04, based on 179 companies in the industry. Companies in the top quartile (top 25%) have a Days Inventory significantly above this median, while those in the bottom quartile fall well below. However, Days Inventory should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Biomaxima's current Days Inventory of 208.42 is 220.4% above the industry median. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Days Inventory mean?
A high Days Inventory can signal that a stock is expensive relative to its fundamentals. Days inventory represents the average amount of days a company holds inventory before selling it. View historical data on Biomaxima and its competitors. For the Medical Diagnostics & Research industry, the median Days Inventory is 65.04 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Biomaxima's current Days Inventory is 208.42, which is 29% above median its own 10-year median of 161.28. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Biomaxima stock overvalued right now?
Biomaxima (FRA:944) has a current Days Inventory of 208.42. The stock's GF Value™ is €2.99, compared to a current price of €1.89 — trading 36.7% below its estimated fair value. The current Days Inventory is 208.42, which is 29% above median its 10-year median of 161.28 and 220.4% above the Medical Diagnostics & Research industry median of 65.04. Biomaxima's overall GF Score™ is 51/100 with 4 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Days Inventory calculated?
Days Inventory is calculated from a company's financial statements. For Biomaxima (FRA:944), the current Days Inventory is 208.42 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Biomaxima (FRA:944) Overvalued in 2026?
Based on GuruFocus' analysis, Biomaxima stock appears to be undervalued.
The current stock price of €1.89 is trading 36.7% below its estimated GF Value™ of €2.99.
Key valuation signals for FRA:944:
Days Inventory: 208.42 (29% above median its 10-year median of 161.28)
GF Value™: €2.99 vs. price of €1.89 (36.7% below fair value)
Industry Position: 220.4% above the Medical Diagnostics & Research median (#146 of 179)
No single metric tells the full story. See the FRA:944 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
BioMaxima SA is a Polish company operating in the market of laboratory diagnostics. It is a manufacturer of microbiological substrates as well as a wide range of reagents and diagnostic equipment. The company is also a distributor of products of recognized multinational diagnostic companies such as: Accelerate Diagnostics, Nova Biomedical, PHC Group, Technoclone, Kabe and Biolog.
51GF Score
Get the complete analysis for FRA:944
Days Inventory is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
FRA:944 has been successfully added to your 
